(2020). Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. J Immunother Cancer.
Chicago Style aipamena"Correction: Tislelizumab in Chinese Patients With Advanced Solid Tumors: An Open-label, Non-comparative, Phase 1/2 Study." J Immunother Cancer 2020.
MLA aipamena"Correction: Tislelizumab in Chinese Patients With Advanced Solid Tumors: An Open-label, Non-comparative, Phase 1/2 Study." J Immunother Cancer 2020.
Kontuz: berrikusi erreferentzia hauek erabili aurretik.